retatrutide 2025 trial results Results: 28.3% Weight Loss Data Retatrutide Weight Loss Results:Trial Data

Elderly patients Older adults are at higher risk for hypoglycemia with insulin therapy, including Toujeo

Survodutide : GLP-1/glucagon dual receptor agonist

In a trial consisting of diabetic and hypertensive patients with a mean HbA1c of 8.59, empagliflozin, compared to placebo, showed a lower number of cerebrovascular events [37]

Compared to placebo, patients receiving retatrutide experienced higher occurrences of nausea, vomiting, decreased appetite, diarrhea, and constipation ( Table 4 )

Mitochondrial dysfunction, characterized by impaired -oxidation capacity and increased ROS formation, fuels the aberrant ROS production [137]

Promoting toxic weight narratives Finally, Willows messaging feeds into disordered eating behaviors and perpetuates unrealistic beauty standards, particularly harmful to young women online